Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Instagram Outage Disrupts Thousands of U.S. Users 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
MALVERN, Pa., March 05, 2018 -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing therapies for the treatment of orphan diseases, today announced the appointment of Nancy Hutson, Ph.D., and Linda Tufts to its board of directors. PhaseBio also announced the retirement of board members Guy Fish, M.D., and Robert Ingram.
“We are pleased to welcome Nancy and Linda to our board of directors. Their extensive industry experience and strategic expertise will be instrumental as we advance the clinical development of our lead therapy, PB1046, in pulmonary arterial hypertension, and move additional orphan product candidates into the clinic, including PB2452, our ticagrelor reversal agent,” said Jonathan P. Mow, Chief Executive Officer of PhaseBio. “I would also like to thank Guy and Bob for their valuable contributions to PhaseBio, which have played a pivotal role in our corporate development and the progress of our pipeline.”
Dr. Hutson has more than 30 years of experience in the pharmaceutical industry. She retired from Pfizer Inc. in 2006 after spending 25 years in research and leadership positions, most recently serving as Senior Vice President of Global Research & Development and Director of Pfizer’s pharmaceutical research and development site Groton / New London Laboratories. Dr. Hutson currently serves on the boards of directors for BioCryst Pharmaceuticals, Inc. and Endo International plc, and on the scientific advisory board of Hatteras Venture Partners. Dr. Hutson received a Ph.D. in physiology and biochemistry from Vanderbilt University and a B.A. in general biology from Illinois Wesleyan University.
“PhaseBio is applying its elastin-like polypeptide technology platform to create novel therapeutics that treat significant unmet needs by enabling both new mechanisms and less frequent dosing,” said Dr. Hutson. “I look forward to working with PhaseBio to advance PB1046 for people suffering from pulmonary arterial hypertension, while also exploring opportunities to expand the application of its exciting technology platform.”
Ms. Tufts has more than 35 years of experience working with companies across the healthcare and life sciences sectors. Currently, Ms. Tufts is General Partner at Fletcher Spaght Ventures and Fletcher Spaght, Inc. Previously, she held positions at the Sony Corporation of America and Bain & Company, Inc. Ms. Tufts serves on the boards of directors at Juventas Therapeutics, Inc., and HistoSonics, Inc. She received an S.M. in management with a concentration in finance from the Massachusetts Institute of Technology (MIT) Sloan School of Management, and also holds an S.B. in electrical engineering and computer science, and an S.B. in humanities and science with a concentration in physics from MIT.
“This is an exciting time for PhaseBio, as the company prepares to advance on key clinical milestones in 2018 that will create value, particularly the initiation of a Phase 1 trial of its ticagrelor reversal agent PB2452 shortly,” said Ms. Tufts. “I am thrilled to join PhaseBio to support the rapid progression of PB2452 and PB1046 through clinical trials and to help them bring novel therapies to patients in need.”
About PhaseBio
PhaseBio Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company developing therapies for the treatment of orphan diseases. PhaseBio is leveraging its proprietary elastin-like polypeptide (ELP) biopolymer technology platform to develop therapies with the potential for less-frequent dosing and better patient compliance. PhaseBio’s lead development candidate, PB1046, is a first-in-class weekly vasoactive intestinal peptide (VIP) receptor agonist for the treatment of pulmonary arterial hypertension. The company is also developing PB2452, a reversal agent for the antiplatelet therapy ticagrelor. PhaseBio is privately owned, with headquarters and research laboratories in Malvern, PA. For more information, please visit www.phasebio.com.
Media Contact:
Laura Bagby, 6 Degrees
(312) 448-8098
[email protected]
